Abstracts Clinical Lymphoma, Myeloma & Leukemia September 2023 S406 5PharmaEssentia Japan KK, Tokyo, Japan. 6PharmaEssentia USA Corp, Burlington, USA Context: There is an unmet need for treatment options in patents with essential thrombocythemia (ET) who require cytoreduction and may or may not have been treated with hydroxyurea (HU) or anagrelide (ANA). Interferons have been shown to improve hematological and molecular responses in MPNs for 30 years, but currently no interferons are approved for the treatment of ET. Objective: To assess the tolerability of ropeginterferon alfa2b-njft (P1101) in adults with ET who live in the US or Canada. Design: Single-arm, open-label study includes a 28-day screening, 28-day titration period, 12-month treatment phase, and a 28-day follow-up period, for a total duration of 15 months. P1101 will be administered every 2 weeks during the treatment phase at each study visit, and once a maintenance dose is identified, bi-weekly minor assessment visits may be replaced with phone visits. A subsequent extension phase will supply P1101 to patients deriving benefit for a total of 3 years of treatment. Setting: Study results will impact the management of patients with ET. Patients or Other Participants: Adults diagnosed with ET according to the WHO 2016 criteria with a platelet count at screening >450x109/L, cytoreductive treatment naïve or with prior HU and/or ANA may participate. Patients with a history or presence of clinically relevant depression, risk of suicide, or autoimmune disease may not participate. Interventions: P1101 will be administered subcutaneously every 2 weeks at the starting dose of 250 mcg (Week 0), 350 mcg (Week 2), and titration to the target dose of 500 mcg (Week 4) and remain fixed for the 12-month treatment period. Subjects currently on HU or ANA will follow a pre-specified dose-tapering schedule. All subjects will receive lowdose aspirin unless contraindicated. Results: The study is recruiting across 27 centers with plans to enroll 64 patients. Main Outcome Measures: The primary endpoint is a durable response defined as the proportion of subjects who achieve simultaneous peripheral blood count remission (platelets ≤400x109/L and WBC <10x109/L) for at least 80% of bi-weekly measurements consecutively between weeks 32-52. Acknowledgement: This study is sponsored by PharmaEssentia USA. NCT05482971. Keywords: MPN, essential thrombocythemia, ropeginterferon alfa-2b-njft, myeloproliferative neoplasm, interferon, phase II, trial-in-progress Hodgkin Lymphoma HL-007 The Role of Interim Positron Emission Tomography (PET)/Computed Tomography (CT) Scans in the Management of Hodgkin Lymphoma: A Single‑Center Study in a Developing Country Saya Azeez MD, Ahmed Yassin MD, Nasherwan Sadiq MD Nanakali Hospital, Erbil, Iraq Background: Monitoring and treatment strategies for Hodgkin lymphoma (HL) have improved in the past decade in Erbil, Iraq, resulting in most patients having a good prognosis. But despite these advances, deaths occur. Aim of Study: To evaluate the prognostic value of interim PET/CT scans in HL patients to predict overall survival (OS) outcomes and progression-free survival (PFS) rates. Patients and Methods: A retrospective cross-sectional study was conducted at Nanakali Hospital in Erbil, in the Kurdistan region of Iraq, by reviewing data of patients with HL who were admitted from January 1, 2014 to December 31, 2019 which yielded a sample of 75 HL patients. The diagnosis of HL by a physician was based on lymph biopsy according to World Health Organization criteria. The PET/CT scan was done after 2 treatment cycles. PET/CT scan of HL patients was done in a private center in Erbil (Media Diagnostic Center). Results: The mean OS (mOS) duration of HL patients was 5.39 years with an OS rate of 92%, and the mean PFS duration of HL patients was 5.04 years with a PFS rate of 76%. The mOS of HL patients with a positive interim PET/CT scan was 4 years with a rate of 75% which was significantly lower than the mOS of HL patients with a negative interim PET/CT scan at 7.2 years with a rate of 95.2% (P<0.001). Conclusions: The interim PET/CT scan is useful in the prognosis of patients with HL and in predicting OS and mortality. Keywords: HL, PET/CT scan, Hodgkin lymphoma, survival, overall survival, progression-free survival HL-043 Insights into Epidemiological Profile and Diagnosis of Hodgkin Lymphoma Vasile Musteata MD, PhD, MPH1,2, Valeria Sevcenco MD1, Rodica Mindruta-Stratan MD, PhD2 1State University of Medicine and Pharmacy “N. Testemitanu”, Chisinau, Republic of Moldova. 2Institute of Oncology, Chisinau, Republic of Moldova Context: The incidence rate of Hodgkin lymphoma (HL) accounts for 24% of all malignant lymphoma cases. HL is characterized by a sizable disease burden (DB) in the advanced stages and different treatment outcomes depending on stage and histological type. Objective: Identify and evaluate the updated epidemiological and diagnostic patterns of HL. Design: We performed a descriptive and cohort study. The staging was realized according to the criteria of Lugano Classification of Malignant Lymphomas. The selected patients’ data were compared at inpatient admission with respect to the stage, histopathological, immunohistochemical, and imaging examinations. Setting: The patients’ follow-up was performed at the comprehensive cancer center and related to the hospitalized and outpatient care. Participants: The study included 60 HL patients treated at the Oncological Institute of Moldova between 20182022. Interventions: The retrospective and prospective patients’ groups were evaluated. The following researching methods were used: epidemiological, descriptive, and comparative statistics and big data transfer. Results: The patients were aged between 20-73 years, with a mean age of 43.0 years. The age category up to 35 years proved to be more common (41.7%). Patients aged 36-50 years accounted for 31.7%. Nodular sclerosis was identified as the
RkJQdWJsaXNoZXIy MTk3NTQxMg==